"We are happy to have newly re-established as an independent practice in order to better serve our community. Columbia Gastroenterology Associates has been an established presence for almost 40 years, and we aim to provide more personal and more responsive care in a friendly atmosphere."

During the past decade, Columbia Gastroenterology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Columbia Gastroenterology Associates" #1 sponsor was "Abbott" with 2 trials, followed by "Vertex Pharmaceuticals Incorporated" with 2 trials sponsored, "Bausch Health Americas, Inc." with 1 trials sponsored, "Biogen" with 1 trials sponsored and "Facet Biotech" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Columbia Gastroenterology Associates" #1 collaborator was "Elan Pharmaceuticals" with 1 trials as a collaborator and "Tibotec, Inc" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Columbia Gastroenterology Associates" are "Crohn's Disease" (4 trials), "Hepatitis C" (2 trials), "Ulcerative Colitis" (2 trials), "Gastrointestinal Disease" (1 trials) and "Hepatitis C, Chronic" (1 trials). Many other conditions were trialed in "Columbia Gastroenterology Associates" in a lesser frequency.

Most popular intervention types in "Columbia Gastroenterology Associates" are "Drug" (9 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Adalimumab" (2 trials), "Ribavirin" (2 trials), "Telaprevir" (2 trials), "Adacolumn" (1 trials) and "Daclizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Columbia Gastroenterology Associates" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Columbia Gastroenterology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Columbia Gastroenterology Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Columbia Gastroenterology Associates, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".